Tiziana Life Sciences plc TLSA 深 滬
等待開盤 09-06 09:30:00 美东时间
1.62
+0.040
+2.53%
華盛通- 最 高1.66
- 今 開1.65
- 成交量 33.94万股
- 最 低 1.51
- 昨 收 1.58
- 總市值 1.90亿
- 52周最高 2.60
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 0.6295
- 委 比 -9.09%
- 總股本 1.17亿
- 歷史最高 12.15
- 量 比 1.89
- 振 幅 9.49%
- 歷史最低 0.41
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tiziana Life Sciences Chairman Gabriele Cerrone Buys 25K Shares At $1.60; Now Holds 36.28% Of Issued Capital
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,
09-05 20:35
Tiziana Life Sciences Announces Purchase of Shares by Chairman
**Tiziana Life Sciences创始人增持股份，Foralumab临床试验进展顺利** Tiziana Life Sciences创始人Gabriele Cerrone增持25,000股，持股比例增至36.28%。公司核心产品Foralumab作为全球唯一在研的全人源抗CD3单抗，在治疗非活动性继发进展型多发性硬化症的临床试验中表现出色。
09-05 12:30
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
Tiziana Life Sciences has initiated a Phase 2a trial for its intranasal foralumab in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disease. The study, conducted at Brigham and Women’s Hospital, aims to assess the therapy's potential to reduce neuroinflammation and slow disease progression by targeting regulatory T cells. MSA affects 15,000–50,000 people in the U.S., with no approved treatments to alter its course. Foraluma...
08-14 12:30
Tiziana to begin testing foralumab in multiple system atrophy
Shares of Tiziana Life Sciences (NASDAQ:TLSA) rose after the FDA approved the mid-stage trial initiation of its lead candidate, intranasal foralumab, in patients with multiple system atrophy. The stoc...
08-11 21:29
FDA Approves Tiziana Life Sciences’ Phase 2a Trial for MSA
An update from Tiziana Life Sciences ( ($TLSA) ) is now available. On August 11...
08-11 21:28
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
Tiziana Life Sciences announced FDA approval of the IND for its Phase 2a trial of intranasal foralumab for Multiple System Atrophy (MSA), a rare, untreatable neurodegenerative disease. The trial will assess the safety and effects of foralumab, a fully human anti-CD3 monoclonal antibody, on microglial activation and clinical outcomes in MSA patients. MSA, with a prevalence of 1.9-4.9 per 100,000 worldwide, causes rapid progression of autonomic and...
08-11 13:00
Tiziana Life Sciences Announced Immunologic Findings From The Treatment Of A Moderate Alzheimer's Disease Patient With Intranasal Foralumab
Transcriptional analysis of white blood cells before and after foralumab therapy revealed profound immune modulatory effects. Significant changes were observed in CD4 cells, CD8 cells, and monocytes, underscoring the
07-21 19:02
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
Tiziana Life Sciences announced significant immunological findings from a study using intranasal foralumab, an anti-CD3 monoclonal antibody, in a moderate Alzheimer's Disease (AD) patient. The treatment showed profound immune modulatory effects, including changes in CD4 cells, CD8 cells, and monocytes, as well as reduced inflammation in microglia PET scans. Unexpectedly, it also increased phagocytosis markers in monocytes, suggesting potential am...
07-21 11:00
Tiziana shares rise on presentation date for foralumab data
Tiziana Life Sciences (NASDAQ:TLSA) shares rose on Friday after the company said that its CEO, Ivor Elrifi, will present data related to its lead drug candidate, intranasal foralumab, for the treatmen...
06-13 21:36
Tiziana Life Sciences to Present Intranasal Foralumab Findings at Bio International Convention
Tiziana Life Sciences ( ($TLSA) ) has provided an update. On June 13, 2025, Tiz...
06-13 20:58
